StockDrifts LogoStockDrifts

Dongsung Pharmaceutical 002210

Company
동성제약Dongsung Pharmaceutical
Insiders
0
Buys
0
Total Value
—
Avg Return
—
Last Filing
2026-04-09

Dongsung Pharmaceutical (002210) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for Dongsung Pharmaceutical is dated 2022-10-13; the most recent is 2026-04-09. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea).

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-04-09BUYCB인수
태광산업
Taekwang Industry
-10.0M₩973+0.0%₩9.7B ($6.8M)
2026-04-09BUYCB인수
아이비케이금융그룹-유암코 중기도약 펀드
IBC Financial Group-Yuamco Mid-Term Jump Fund
-8.5M₩973+0.0%₩8.3B ($5.7M)
2026-04-09BUYCB인수
유암코제약산업제1호기업재무안정사모투자
Yuamco Pharmaceutical Industry No. 1 Corporate Financial Stability Private Investment
-31.5M₩973+0.0%₩30.6B ($21.3M)
2026-03-31BUY제3자배정유상증자
유암코제약산업제1호기업재무안정사모투자
Yuamco Pharmaceutical Industry No. 1 Corporate Financial Stability Private Investment
-31.5M₩973+0.0%₩30.6B ($21.3M)
2026-03-31BUY제3자배정유상증자
아이비케이금융그룹-유암코 중기도약 펀드
IBC Financial Group-Yuamco Mid-Term Jump Fund
-8.5M₩973+0.0%₩8.3B ($5.7M)
2026-03-31BUY제3자배정유상증자
태광산업
Taekwang Industry
-30.0M₩973+0.0%₩29.2B ($20.3M)
2025-06-24SELL기타
나원균
Na Won-gyun
CEO-300.0K₩973+0.0%₩292M ($203K)
2025-04-22BUY장외매수
브랜드리팩터링
Brand refactoring
-1.6M₩1,885-48.4%₩3.0B ($2.1M)
2025-04-21BUY장외매수
브랜드리팩터링
Brand refactoring
-1.3M₩1,910-49.1%₩2.4B ($1.7M)
2025-02-26SELL장외매도
이양구
Lee Yang-gu
--766.4K₩1,950+50.1%₩1.5B ($1.0M)
2025-02-26BUY장외매수
나원균
Na Won-gyun
moving766.4K₩1,950-50.1%₩1.5B ($1.0M)
2022-10-13SELL증여
이양구
Lee Yang-gu
--300.0K₩3,445+71.8%₩1.0B ($718K)

Frequently asked questions

Who has been buying Dongsung Pharmaceutical stock?
0 distinct insiders have filed 0 disclosed insider purchases in Dongsung Pharmaceutical (002210), most recently on 2026-04-09. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Dongsung Pharmaceutical have?
Dongsung Pharmaceutical has 0 buy-side and 0 sell-side disclosures on record, spanning 2022-10-13 to 2026-04-09.
Where does StockDrifts get Dongsung Pharmaceutical insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Dongsung Pharmaceutical. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.